Page last updated: 2024-10-30

losartan and Death, Sudden, Cardiac

losartan has been researched along with Death, Sudden, Cardiac in 16 studies

Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position

Death, Sudden, Cardiac: Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)

Research Excerpts

ExcerptRelevanceReference
" We measured the QRS duration and QT intervals from the baseline 12-lead electrocardiograms in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study, which included hypertensive patients with electrocardiographic evidence of left ventricular hypertrophy randomized to either losartan-based or atenolol-based treatment to lower blood pressure."9.11QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Jern, S; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M, 2004)
"Differences in QT dispersion (a predictor for sudden death) were observed in a subgroup of patients in the ELITE heart failure study of losartan compared with captopril, and may explain improved survival with losartan."9.09Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group. ( Brooksby, P; Cowley, AJ; Klinger, G; Pitt, B; Robinson, PJ; Segal, R, 1999)
"The relationship of SCD to new-onset AF was evaluated in 8831 hypertensive patients with electrocardiographic left ventricular hypertrophy with no history of AF, in sinus rhythm on their baseline electrocardiogram, randomly assigned to losartan- or atenolol-based treatment."5.17Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. ( Bang, CN; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K, 2013)
"The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study included 9193 patients 55 to 80 years of age with essential hypertension and ECG LV hypertrophy by gender-adjusted Cornell product (CP) (RaVL+SV(3) [+6 mm in women])."5.12Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Olsen, MH; Thygesen, K; Wachtell, K, 2007)
" We measured the QRS duration and QT intervals from the baseline 12-lead electrocardiograms in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study, which included hypertensive patients with electrocardiographic evidence of left ventricular hypertrophy randomized to either losartan-based or atenolol-based treatment to lower blood pressure."5.11QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Jern, S; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M, 2004)
"The OPTIMAAL trial randomized 5477 patients with heart failure or evidence of left ventricular dysfunction following acute MI to losartan or captopril."5.11Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. ( Cleland, JG; Dickstein, K; Kjekshus, J; Orn, S; Romo, M, 2005)
"Differences in QT dispersion (a predictor for sudden death) were observed in a subgroup of patients in the ELITE heart failure study of losartan compared with captopril, and may explain improved survival with losartan."5.09Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group. ( Brooksby, P; Cowley, AJ; Klinger, G; Pitt, B; Robinson, PJ; Segal, R, 1999)
"Rats harboring the human renin and angiotensinogen genes (dTGR) feature angiotensin (ANG) II/hypertension-induced cardiac damage and die suddenly between wk 7 and 8."3.74Angiotensin II-induced sudden arrhythmic death and electrical remodeling. ( Dechend, R; Dietz, R; Fiebeler, A; Fischer, R; Gapelyuk, A; Gratze, P; Gruner, A; Gruner, K; Luft, FC; Muller, DN; Qadri, F; Schirdewan, A; Shagdarsuren, E; Wellner, M, 2007)
"In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality--especially cardiovascular mortality--in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan."3.72Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Edelman, JM; Ibsen, H; Lindholm, LH; Olsen, MH; Snapinn, S; Wachtell, K, 2003)
"Hypertension is a major influence on the development of LVH."2.43Ventricular hypertrophy and hypertension: prognostic elements and implications for management. ( Devereux, RB; Krauser, DG, 2006)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (25.00)18.2507
2000's11 (68.75)29.6817
2010's1 (6.25)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Okin, PM4
Bang, CN1
Wachtell, K3
Hille, DA1
Kjeldsen, SE3
Dahlöf, B5
Devereux, RB5
Morin, DP1
Oikarinen, L2
Viitasalo, M2
Toivonen, L2
Nieminen, MS3
John, M1
Aronow, WS1
Lindholm, LH2
Edelman, JM1
Ibsen, H2
Borch-Johnsen, K1
Olsen, MH2
Snapinn, S1
Ong, HT1
Chong, AY1
Lip, GY1
Jern, S1
Orn, S1
Cleland, JG1
Romo, M1
Kjekshus, J1
Dickstein, K1
Krauser, DG1
Fischer, R1
Dechend, R1
Gapelyuk, A1
Shagdarsuren, E1
Gruner, K1
Gruner, A1
Gratze, P1
Qadri, F1
Wellner, M1
Fiebeler, A1
Dietz, R1
Luft, FC1
Muller, DN1
Schirdewan, A1
Thygesen, K1
Rump, LC1
Oberhauser, V1
Schwertfeger, E1
Schollmeyer, P1
Brooksby, P1
Robinson, PJ1
Segal, R1
Klinger, G1
Pitt, B1
Cowley, AJ1
Riegger, GA1
Topol, E1
Gavras, I1
Gavras, H1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260]Phase 3496 participants (Actual)Interventional1995-06-30Completed
Assessment of Prolonged Paced QRS Duration as a Marker of Sudden Cardiac Death in Subjects With Implantable Cardioverter-defibrillators[NCT01948206]100 participants (Actual)Observational2013-10-31Terminated (stopped due to Ran out of funds)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

3 reviews available for losartan and Death, Sudden, Cardiac

ArticleYear
Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
    Herz, 2006, Volume: 31, Issue:4

    Topics: Adrenergic Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert

2006
[ACE inhibitors or AT1 receptor antagonists?].
    Deutsche medizinische Wochenschrift (1946), 1999, Sep-24, Volume: 124 Suppl 2

    Topics: Age Factors; Aged; Angiotensin I; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme In

1999
The antiarrhythmic potential of angiotensin II antagonism: experience with losartan.
    American journal of hypertension, 2000, Volume: 13, Issue:5 Pt 1

    Topics: Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardi

2000

Trials

7 trials available for losartan and Death, Sudden, Cardiac

ArticleYear
Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy.
    Circulation. Arrhythmia and electrophysiology, 2013, Volume: 6, Issue:2

    Topics: Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Confidence Intervals; Death, Sudden, C

2013
QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study.
    European heart journal, 2009, Volume: 30, Issue:23

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Bundle-Branch Block; Death, Sudden, Card

2009
QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
    Hypertension (Dallas, Tex. : 1979), 2004, Volume: 43, Issue:5

    Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Cause of Death; Death, Sudden, Cardiac; Elec

2004
Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction.
    The American journal of medicine, 2005, Volume: 118, Issue:7

    Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cause of Death; Death, Sudden, Cardiac; Female; Follo

2005
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
    Circulation, 2007, Aug-14, Volume: 116, Issue:7

    Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Death, Sudden, Cardiac; Double-Blind Met

2007
Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group.
    Lancet (London, England), 1999, Jul-31, Volume: 354, Issue:9176

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Captopril; Cardiotonic Agent

1999
ACE inhibitors still the drug of choice for heart failure--and more.
    Lancet (London, England), 1999, Nov-20, Volume: 354, Issue:9192

    Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Death, Sudden, Cardiac

1999

Other Studies

6 other studies available for losartan and Death, Sudden, Cardiac

ArticleYear
Might losartan reduce sudden cardiac death in diabetic patients with hypertension?
    Lancet (London, England), 2003, Aug-23, Volume: 362, Issue:9384

    Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Comorbidit

2003
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
    Lancet (London, England), 2003, Aug-23, Volume: 362, Issue:9384

    Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Comorbidity; Dea

2003
LIFE: losartan versus atenolol.
    Lancet (London, England), 2003, Oct-25, Volume: 362, Issue:9393

    Topics: Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus; Drug Ther

2003
LIFE: losartan versus atenolol.
    Lancet (London, England), 2003, Oct-25, Volume: 362, Issue:9393

    Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diab

2003
Angiotensin II-induced sudden arrhythmic death and electrical remodeling.
    American journal of physiology. Heart and circulatory physiology, 2007, Volume: 293, Issue:2

    Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Animals, Genetica

2007
Experimental evidence to support ELITE.
    Lancet (London, England), 1998, Feb-28, Volume: 351, Issue:9103

    Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Death,

1998